PPD DEVELOPMENT LP
- Unique Entity ID (UEI)
- ZANENSW6C665
- Parent company
- JAGUAR HOLDING COMPANY II (UEI MVQ8HNL9ULH3)
- Registered address
- WILMINGTON, NC, district NC-07
- Other names on record
- APPLIED BIOSCIENCE INTERNATIONAL, PPD DEVELOP; PHARMACEUTICAL PRODUCT DEVELOP; PHARMACEUTICAL PRODUCT DEVELOPMENT; PHARMACEUTICAL PRODUCT DEVELOPMENT INC; PHARMACEUTICAL PRODUCT DEVELOPMENT INC.; PHARMACEUTICAL PRODUCT DEVELOPMENT, INC; PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.; PPD DEVELOPMENT, L.P.; PPD DEVELOPMENT, LP
Dollars are contract obligations in the fiscal year, as USAspending adds them up from each award's transactions. A contract's full value can be larger and run over several years. A figure below zero is money taken back from contracts signed earlier.
Source: USAspending.gov, the Treasury’s public record of federal spending. Our copy was saved November 17, 2026.
Which agencies pay this vendor, and where the work is done
Fiscal year 2027: $2,945,851
| Agency | Contract dollars |
|---|---|
| Department of Health and Human Services | $2,945,851 |
| District where the work is done | Contract dollars |
|---|---|
| NC-07David Rouzer | $2,945,851 |
Fiscal year 2026: $50,501,887.75
| Agency | Contract dollars |
|---|---|
| Department of Health and Human Services | $50,501,887.75 |
| District where the work is done | Contract dollars |
|---|---|
| NC-07David Rouzer | $50,515,379.47 |
| MD-08Jamie Raskin | -$13,491.72 |
Largest awards
The largest contract awards with activity from October 1, 2025 to September 30, 2027, by each award's total amount over its whole life. 0 rows of the answer belong to related companies and are left out.
| Award | Agency | Where the work is done | Award total | Start |
|---|---|---|---|---|
| 75A50123C00045ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ | Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | WILMINGTON, NC-07 | $126,485,055 | Ends September 28, 2029 |
| 75A50124C00001BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS. | Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | WILMINGTON, NC-07 | $117,399,278 | Ends September 30, 2030 |
| 75N93024F00001NIAID CLINICAL SITE MONITORING (NCSM) | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $73,196,564 | Ends January 31, 2027 |
| 75N93022C00014NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) CLINICAL SITE MONITORING CENTER (CSMC) | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $36,391,559 | Ends June 29, 2027 |
| HHSN272201200004CTAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $27,036,076.33 | Ends August 20, 2026 |
| 75N93024F00002COMPREHENSIVE AND RAPID RESPONSE FOR NIAID RESEARCH PROGRAMS HIV AND OTHER INFECTIOUS DISEASES CLINICAL RESEARCH SUPPORT SERVICES (CRSS) | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $26,101,778 | Ends August 14, 2027 |
| HHSN272201200002CR&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH) | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $21,947,371.89 | Ends October 31, 2021 |
| 75N93022C00001REGULATORY MANAGEMENT CENTER (RMC) | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $20,372,255 | Ends October 31, 2027 |
| 75N93019F00131TO PROVIDE MONITORING SERVICES FOR ONE (1) PHASE III CLINICAL TRIAL, A5300B/PHOENIX | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $5,696,076.64 | Ends December 14, 2025 |
| 75N93026F00001DAIDS MONITORING FOR 1 PHASE III STUDY: A5300B/I2003B (PHOENIX) | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $3,092,829 | Ends December 14, 2026 |
| 75N93023F00001EPCTU | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $2,791,811 | Ends January 31, 2026 |
| 75D30121C11269TBTC MONITORING | Department of Health and Human ServicesCenters for Disease Control and Prevention | WILMINGTON, NC-07 | $2,054,175.16 | Ends June 27, 2024 |
| 75N98026F00001TASK ORDER AWARD- PHASE I CLINICAL TRIALS FOR THE DEVELOPMENT OF NEUROTHERAPEUTICS- DTI-117 IN HEALTHY VOLUNTEERS/SAD AND MAD CT | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $2,016,831 | Ends April 28, 2027 |
| 75F40124C00134BAA-FY24C3CP5-UNDERSTANDING HETEROGENEITY IN PREFERENCES FOR CLINICAL TRIAL PARTICIPATION IN DIVERSE PATIENT POPULATIONS. | Department of Health and Human ServicesFood and Drug Administration | WILMINGTON, NC-07 | $1,299,218 | Ends November 22, 2027 |
| 75N93022F00001TASK ORDER 75N93022F00001 BASE AWARD | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $905,501 | Ends January 13, 2027 |
| 75F40124C00117FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASURE | Department of Health and Human ServicesFood and Drug Administration | WILMINGTON, NC-07 | $724,461 | Ends July 15, 2027 |
| 75N92019C00005ACQUISITION TITLE: CLINICAL SITE AND STUDY MONITORING SUPPORT SERVICES FOR THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE'S HYPERTENSION OUTCOMES FOR T4 RESEARCH WITHIN LOWER MIDDLE-INCOME COUNTRIES (HY-TREC) | Department of Health and Human ServicesNational Institutes of Health | BETHESDA, MD-08 | $654,560.53 | Ends July 25, 2023 |
| 75N95024F00001RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. CLINICAL STUDY PROTOCOL DEVELOPMENT. TASK ORDER 02. 06/17/2024 - 06/16/2029. BASE AND EXERCISE 2 UNITS OF OPTION QUANTITY 1. | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $324,420 | Ends June 16, 2029 |
| 75N95023F00001REGULATORY CONSULTING ASSISTANCE FOR MEDICAL DEVICE DEVELOPER. RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. TASK ORDER 02. 09/15/2023 - 09/14/2024. | Department of Health and Human ServicesNational Institutes of Health | WILMINGTON, NC-07 | $63,603.26 | Ends December 31, 2024 |
| 75N93021F00001COMPREHENSIVE AND RAPID RESPONSE FOR NIAID RESEARCH PROGRAMS | Department of Health and Human ServicesNational Institutes of Health | BETHESDA, MD-08 | $0 | Ends August 31, 2022 |
Subcontracts it reported
A prime contractor reports the subcontracts it gives under an award (first-tier subawards). These are the largest it reported under its three largest awards, from every year of each award.
No subcontract is reported under this vendor’s largest awards.
Lobbying reports and campaign receipts that name this vendor
No lobbying report, organization page or FEC receipt in our saved records has this vendor’s name or its parent company’s name.
A name is matched only when it is the same name under the exact-name rule: letters and numbers alike, "&" read as "and", a leading "the" and one closing legal form (Inc, LLC, Corp, Corporation, Co, LP, LLP) set aside. A near name is never a match. Each match says which name matched.